Abstract:
Objective: To determine the frequency of parenteral Acyclovir-induced Acute Kidney Injury (AKI) in patients with viral encephalitis. Study Design: Descriptive study. Place and Duration of the Study: Department of Neurology, Liaquat National Hospital, Karachi, from January to December 2021. Methodology: A total of 89 suspected and proven cases of encephalitis receiving IV Acyclovir were collated. All had extensive medical histories and underwent CSF studies with +/- brain imaging. CSF routine and viral PCR were done. Acyclovir-induced AKI was de ned as a rise in serum creatinine of >0.3 mg/dl in 48 h or by e1.5 times the baseline value, and its severity was staged into 1 (risk), 2 (injury), and 3 (failure) according to the KDIGO guidelines (Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, 2012). Patients variables, including age, gender, presenting features, comorbid conditions, and CSF ndings, were divided into two groups, i.e. with and without AKI. Results: This research included 89 patients with a mean age of 48 years. AKI occurred in 34 patients (38.2%). The frequency of AKI with Stage 1 was 24%, Stage 2 was 44%, and Stage 3 was 32%; approximately two-thirds of cases were in Stage 2 and 3 (p >0.05). Five patients (5.6%) from Stage 3, required dialysis. Conclusion: AKI is an important adverse e ect of parenteral acyclovir, which necessitates its early identi cation and timely management. Renal function monitoring is essential for patients on Acyclovir treatment as they are at risk for AKI.
Page(s):
151-155
DOI:
DOI not available
Published:
Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 2, Year: 2024
Keywords:
Creatinine
,
Acute Kidney Injury
,
acyclovir
,
Kidney Disease Improving Global Outcomes
,
Viral Encephalitis